Pathogenesis, clinical findings and management of acute and chronic gout

Minerva Medica

Volumn 97, Issue 6, 2006, Pages 495-509

  Corrado, A ^a,b   D'Onofrio, F ^a   Santoro, N ^a   Melillo, N ^a   Cantatore, F P ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Rheumatology Clinic Mario Carrozzo   (Italy)

Author keywords

Gout, phisiopathology; Gout, therapy; Uric acid

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; BENZBROMARONE; BETAMETHASONE; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; CYTOKINE; ETORICOXIB; FENOFIBRATE; INDOMETACIN; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PREDNISONE; PYRAZINAMIDE; TRIAMCINOLONE ACETONIDE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; URIC ACID;

ABDOMINAL PAIN; ALOPECIA; BLOOD DISEASE; BONE MARROW SUPPRESSION; CEREBROVASCULAR DISEASE; DIARRHEA; DIET; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ANTAGONISM; DRUG CHOICE; DRUG HALF LIFE; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; ERYTHEMA; FEVER; GASTROINTESTINAL SYMPTOM; GLYCOGEN SYNTHESIS; GOUT; GRANULOMATOUS HEPATITIS; HEREDITY; HUMAN; HYPERURICEMIA; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIVER NECROSIS; LOW DRUG DOSE; MYELOFIBROSIS; NAUSEA; NEPHROLITHIASIS; ONSET AGE; OSTEOPHYTE; PATHOGENESIS; POLYCYTHEMIA; PRURITUS; PURINE METABOLISM; RASH; REVIEW; SKIN NECROSIS; SYNOVIAL FLUID; VASCULITIS; VOMITING; ACUTE DISEASE; CHEMISTRY; CHRONIC DISEASE; CRYSTALLIZATION; METABOLISM;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; COLCHICINE; CRYSTALLIZATION; GOUT; HUMANS; RENAL INSUFFICIENCY; URIC ACID;

EID: 33847768123     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Schramm VL, Grubmeyer C. Phosphoribosyltransferase mechanisms and roles in nucleic acid metabolism. Prog Nucleic acid Res Mol Biol 2004;78:261-304.
2. Howell RR, Seegmiller JE. Uricolysis by human leukocytes. Nature 1962;196:482-3.
3. Gutman AB. Renal excretion of uric acid in normal and gouty man. Arthritis Rheum 1965;8:665-70.
4. Praetorius E, Kirk JE. Hyperuricemia with evidence for tubular elimination of uric acid. J Lab Clin Med 1950;35:865-8.
5. Yu TF, Berger L. A study of the paradoxycal effects of salicylate in low, intermediate and high dosages on the renal mechanism for excretion of urate in man. J Clin Invest 1959;38:1298-315.
6. Nugent CA, McDiarmid WD, Tyler FH. Renal excretion of urate in patients with gout. Arch Intern Med 1964;113:115-21.
7. Loenen HM, Eshuis H, Löwik MR, Schouten EG, Hulshof KF, Odink J et al. Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch nutrition surveillance system). J Clin Epidemiol 1990;43:1283-303.
8. Gibson T, Rodgers AV, Simmonds HA, Court-Brown F, Todd E, Meilton V. A controlled study of diet in patients with gout. Ann Reum Dis 1983;42:123-7.
9. Fam AG. Gout, diet and insulin resistance syndrome. J Rheumatol 2002;29:1350-5.
10. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1903-103.
11. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
12. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, dairy products, and serum uric acid level: the Third National health and Nutrition Examination Survey. Arthritis Rheum 2005;52:283-9.
13. Puing JG, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. J Clin Invest 1984;74:936-41.
14. Shadick NA, Kim R, Weiss S, Liang MH, Sparrow D, Hu H. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the Normative Aging Study. J Rheumatol 2000;27:1708-12.
15. Choi HK, Atkinson K, Karlson EW. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81.
16. Lieber CS. Hyperuricemia induced by alcool. Arthritis Rheum 1965;8:786-91.
17. Gibson T, Rodgers AV, Simmonds HA, Toseland P. Beer drinking, and its effect on uric acid. Br J Rheumatol 1984;23:203-9.
18. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;15:341-5.
19. Lin KC, Lin HY, Chou P. The interaction between SUA level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-5.
20. Dessein PH, Shipton AE, Stanwix AE. Beneficial effects of weight loss associated with moderate calorie/carbohydreaye restriction, and increased proportional intake of protein and unsatured fat on serum and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000;59:539-43.
21. Blumberg BS. Heredity of gout ad hyperuricemia. Arthritis Rheum 1965;8:627-34.
22. Van Bogaert P, Ceballos I, Desguerre I, Telvi L, Kamoun P, Ponsot G. Lesch-Nyhan syndrome in a girl. J Inherit Metab Dis 1992;15:790-1.
23. Sorensen LB. Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency. J Clin Invest 1970;49:968-78.
24. Becker MA. Inherited superactivity of phosphoribosylpyrophosphate synthase. Association of uric acid overproduction and sensorineural deafness. Am J Med 1988;85:383-90.
25. Weinman EJ, Eknojan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest 1975;55:283-91.
26. Kelley WN, Rosenbloom FM, Seegmiller JE, Howell RR. Excessive production of uric acid in type 1 glycogen storage disease. J Pediatr 1968;72:488-96.
27. McGill W. Got and other crystal-associated arthropathies. Baillieres Clin Rheumatol 2000;14:445-60.
28. Weissmann G, Rita GA. Molecular basis of gouty inflammation. Interaction of monosodium urate crystals with lysosomes and liposomes. Nature 1972;240:167-72.
29. McGill NW, Dieppe PA. Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis 1991;50:558-61.
30. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972;15:189-92.
31. Dieppe PA, Doherty M. The role of particles in the pathogenesis of joint disease. Curr Topic Pathol 1982;71:199-233.
32. Wilcox WR, Khalef A. Nucleation of monosodium urate crystals. Ann Rheum Dis 1975;34:332-9.
33. Terkeltaub RA, Ginsberg MH. The inflammatory reaction to crystals. Rheum Dis Clin North Am 1988;14:353-64.
34. Nagase M, Baker DG, Schumacher HR. Immunglobulin G coating on crystals and ceramics enhances polymorphonuclear cell superoxide production: correlation with immunoglobulin G adsorbed. J Rheumatol 1989;16:971-6.
35. Ortiz-Bravo E, Sieck MS, Schumacher HR Jr. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluids from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum 1993;36:1274-85.
36. Terkeltaub RA, Dyer CA, Curtiss LK. Apoliproprotein (apo) E inhibits the capacity of monosodium urate to stimulate neutrophils. J Clin Invest 1991;87:20-6.
37. Pascuale E. Persistence of monosodium urate crystal and low grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-5.
38. Chapman PT, Yarood H, Harrison AA, Stocker CJ, Jamar F, Gundel RH et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997;40:955-65.
39. Getting SJ, Di Filippo C, Lam CW, Rossi F, D'Amico M. Investigating into the potential anti-inflammatory effects of endothelin antagonist in a murine model of experimental monosodium urate peritonitis. J Pharmacol Exp Ther 2004;310:90-7.
40. Pekin TJ Jr, Zvaiffler NJ. Hemolytic complement in synovial fluid. J Clin Invest 1964;43:1372-82.
41. Hasselbacher P. C3 activation by monosodium urate monohydrate and other cystallime material. Arthritis Rheum 1979;22:571-8.
42. Doherty M, Whicher JT, Dieppe PA. Activation of the alternative patchway of complement by monosodium urate monohydrate crystals and other inflammatory particles. Ann Reum Dis 1983;42:285-91.
43. Tramontini N, Huber C, Liu-Bryan R, Terkeltaub RA, Kilgore KS. Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum 2004;50:2633-9.
44. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein signaling and activation of activator protein 1 and nuclear factor kappa B transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in nomocytic cells. Arthritis Rheum 2000;43:1145-55.
45. Dalbeth N, Haskard DO. Inflammation and tissue damage in crystal deposition disease. Curr Opin Rheumatol 2005;17:314-8.
46. Jaramillo M, Godbout M, Naccache PH, Olivier M. Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals. J Biol Chem 2004;279:52797-805.
47. Schiltz C, Lioté F, Prudhommeaut F, Meunier A, Champy R, Callebert J et al. Monosodium urate crystal-induced imflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum 2002;46:1643-50.
48. Lunam CA, Gentle MJ. Substance P immunoreactive nerve fibres in the domestic chick ankle joint before and after acute urate arthritis. Neurosci Lett 2004;354:87-90.
49. Lioté F, Bardin T. Pourquoi la crise de goutte s'interrompt-elle spontanément? In: De Sèze S, Ryckewaert A, Khan FM, Guérin C editors. L'Actualité Rhuematologique. Paris: Expansion Scientifique Française; 1995. p. 260-8.
50. Matsukawa A, Yoshimura T, Maeda T, Takahashi S, Ohkawara S, Yoshinaga M. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1β, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998;78:559-69.
51. Lioté F, Prudhommeaux F, Schiltz C, Champy R, Herbelin A, Ortiz-Bravo E et al. Inhibition and prevention of monosodium urate crystal-induced inflammation in vivo by transforming growth factor α-1. Arthritis Rheum 1996;39:1192-8.
52. Yagnik DR, Hillyer P, Marshall D, Smythe CD, Krausz T, Haskard DO et al. Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflammation in gout. Arthritis Rheum 2000;43:1779-89.
53. Pascual E, Pedraz T. Gout. Curr Opin Rheumatol 2004;16:282-6.
54. Rubin BR, Burton N, Navarra S, Antigua J, Londono J, Pryhuber KG et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum 2004;50:598-606.
55. Schlesinger N, Schumacher R Jr. Gout: can management be improved? Curr Opin Rheumatol 2001;13:240-4.
56. Ahbern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Aust NZ J Med 1987;17:301-4.
57. Guazzo E. Use of intravenous colchicine for podagra. Am Fam Physician 1999;60:2504-5.
58. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17:319-24.
59. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute gouty attacks with a small dose of intra-articular triamcinolone acetonide. J Rheumatol 1999;26:2285-6.
60. Gordon GV, Schumacher R. Management of gout. Am Fam Physician 1969;10:62-6.
61. Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979;10:231-54.
62. Alloway JA, Moriarty MJ, Hoogland Yt, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993;20:111-3.
63. Wortmann RL. Effective treatment of gout: an analogy. Am J Med 1998;105:513-4.
64. Bem-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28:48-59.
65. Mikuls TR, MacLean CH, Olivieri J. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43.
66. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003;327:1275-6.
67. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995;22:1621-3.
68. Ferraz MB. An evidence based appraisal of the management of tophaceous interval gout. J Rheumatol 1995;22:1618-20.
69. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
70. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004;71:481-5.
71. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349:1647-55.
72. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcrection of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002;47:610-3.
73. Feher MD, Hepbum AL, Hogart MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003;42:321-5.
74. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-5.